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ABSTRACT
Diabetic nephropathy may occur, in part, as a result of intrarenal oxidative stress. NADPH oxidases comprise
the only known dedicated reactive oxygen species (ROS)–forming enzyme family. In the rodent kidney, three
isoforms of the catalytic subunit of NADPH oxidase are expressed (Nox1, Nox2, and Nox4). Here we show
that Nox4 is the main source of renal ROS in a mouse model of diabetic nephropathy induced by streptozo-
tocin administration in ApoE2/2 mice. Deletion of Nox4, but not of Nox1, resulted in renal protection from
glomerular injury as evidenced by attenuated albuminuria, preserved structure, reduced glomerular accumu-
lation of extracellular matrix proteins, attenuated glomerular macrophage infiltration, and reduced renal
expression of monocyte chemoattractant protein-1 and NF-kB in streptozotocin-induced diabetic ApoE2/2
mice. Importantly, administration of the most specific Nox1/4 inhibitor, GKT137831, replicated these reno-
protective effects of Nox4 deletion. In human podocytes, silencing of the Nox4 gene resulted in reduced
production of ROS and downregulation of proinflammatory and profibrotic markers that are implicated in
diabetic nephropathy. Collectively, these results identify Nox4 as a key source of ROS responsible for kidney
injury in diabetes and provide proof of principle for an innovative small molecule approach to treat and/or
prevent chronic kidney failure.
J Am Soc Nephrol 25: 1237–1254, 2014. doi: 10.1681/ASN.2013070810
CKD is a major complication of diabetes. Further-
more, diabetes remains the most common cause of
end stage renal failure and need for kidney trans-
plantation.1 The underlying mechanisms responsible
for diabetic nephropathy remain to be fully defined.
Therefore, effective and mechanism-based therapies
are not available. It has been hypothesized that dia-
betes mellitus causes renal oxidative stress, that is,
increased levels of reactive oxygen species (ROS), re-
sulting in glomerular damage. Accordingly, oxidative
stress is increasingly considered to be a major
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contributor to the development and progression of diabetic ne-
phropathy.2 Various renal sources of ROShave been suggested to
be relevant in the diabetic kidney. These include auto-oxidation
of glucose, advanced glycation, glycolysis, glucose-6-phosphate
dehydrogenase, sorbitol/polyol pathway flux, hexosamine path-
way flux, mitochondrial respiratory chain, xanthine oxidase,
uncoupled nitric oxide synthase, and NADPH oxidases.2,3
Among these sources,NADPHoxidasesare suggested toplaya
pivotal role in thedevelopment andprogressionof renal injury in
animal models of type 1 and type 2 diabetic nephropathy4–6 and
hence represent a potentially important novel target. NADPH
oxidases are the only enzymes known to be solely dedicated to
ROS generation. Seven isoforms of their catalytic subunit exist
(Nox1–5; Duox1 and 2). Nox isoforms depend to varying degrees
on additional subunits.7–10 Among these isoforms, Nox1, Nox2,
and Nox4 are expressed in the renal cortex. In streptozotocin-
induced diabetic nephropathy, expression of Nox4, Nox2, and
another subunit, p22phox, are all upregulated.11–13With respect
to Nox2, our own studies in streptozotocin-induced diabetic
Nox2 knockout (KO)mice have shown increased susceptibility
to infections and 100% mortality at week 20 of diabetes.14 We
thus did not consider Nox2 blockade a priority in this study
addressing strategies to reduce diabetic nephropathy.
Nox4, originally termed Renox, is highly expressed in renal
tissues.15–18 The role of Nox4 in diabetic nephropathy remains
controversial. Nox4 downregulation by systemic administration
of antisense oligonucleotides, albeit for a short period of only 2
weeks, reduced renal and glomerular hypertrophy and attenuated
the increased expression of fibronectin in renal cortex and glo-
meruli in streptozotocin-induced diabetic rats.19 However, the
Nox4 antisense oligonucleotidemay not be absolutely specific for
Nox4. Furthermore, other authors have suggested either no ef-
fect20 or a protective role of Nox4 in diabetic nephropathy or in
other models of renal fibrosis.21 With respect to Nox1, this iso-
form appears to play a major role in diabetic macrovascular dis-
ease14but not much is known about the role of Nox1 in diabetic
nephropathy. Thus, it remains to be determined which Nox iso-
form plays the most critical role in diabetic kidney disease.
Here we report for the first time a direct comparison of the
long-term effects of Nox1 and Nox4 deletion in the develop-
ment and progression of diabetic nephropathy, by directly
comparing renal injury in streptozotocin-induced diabetic
Nox12/yApoE2/2 and Nox42/2ApoE2/2 double KO mice and
their respective wild-type (WT) control mice. In addition, the
genetic deletion studies were complemented by a pharmaco-
logic intervention study using the currently most specific Nox
inhibitor, GKT137831.22 Key findings in the in vivo studies
were confirmed in vitro using human podocytes.
RESULTS
Metabolic Parameters
First, we investigated the effects of Nox1 and Nox4 deletion as
well as GKT137831 treatment onmetabolic control in diabetic
mice. Induction of diabetes was associated with reduced body
weight, elevated plasma glucose, and glycated hemoglobin
levels in diabetic Nox4+/+ApoE2/2, Nox1+/yApoE2/2, and
ApoE2/2 mice compared with their respective nondiabetic
controls. Diabetic animals also showed a significant elevation
in serum cholesterol, triglyceride, and LDL levels compared
with their respective nondiabetic controls. Neither genetic de-
letion of Nox4 or Nox1 had any effect on the diabetes-induced
changes in body weight, glycemic control, or lipid parameters
(Table 1). Furthermore, no changes in metabolic parameters
were seen with pharmacologic Nox inhibition using
GKT137831 in ApoE2/2 mice for 20 weeks (Table 2). In ad-
dition, systolic BP was similar in all groups. The kidney
weight/body weight ratio was significantly increased in di-
abeticmice. This tended to be attenuated in diabeticNox42/2
ApoE2/2 mice compared with diabetic Nox4+/+ApoE2/2
mice (P=0.08) and was significantly reduced in
GKT137831-treated diabetic ApoE2/2 mice compared with
untreated diabetic ApoE2/2 mice (P,0.05). However, the
kidney weight/body weight ratio was unchanged in diabetic
Nox12/yApoE2/2 mice compared with diabetic Nox1+/yApoE2/2
mice (Tables 1 and 2).
Renal Function Parameters
Albuminuria is a key feature of diabetic nephropathy. There-
fore, we investigated the effect of Nox1 or Nox4 deletion on
albuminuria development and compared the effects to treatment
with the Nox inhibitor, GKT137831, in diabeticApoE2/2mice.
Albuminuria tended to be reduced after 10 weeks of diabetes in
Nox42/2ApoE2/2mice comparedwith diabeticNox4+/+ApoE2/2
mice, but this effect did not reach statistical significance (Figure
1A). However, after 20 weeks of diabetes, albuminuria was
significantly attenuated in diabetic Nox42/2ApoE2/2 mice
compared with diabetic Nox4+/+ApoE2/2 mice (P,0.05) (Fig-
ure 1A). Similarly to deleting Nox4, GKT137831 treatment of
diabetic ApoE2/2 mice protected against development of albu-
minuria after 10 and 20weeks of diabetes (Figure 1C). In contrast,
albuminuria was unaffected in diabetic Nox12/yApoE2/2 mice
(Figure 1B). Similar effects were also observed when the data
were expressed as the urinary albumin/creatinine ratio after 10
and 20 weeks of diabetes (Figure 1, D–F).
Renal Structural Assessment
Diabetic nephropathy is associated with structural abnormal-
ities including glomerulosclerosis and specifically mesangial
expansion. Indeed, glomerulosclerosis and mesangial area
expansion were significantly increased after 20 weeks of
diabetes inNox4+/+ApoE2/2mice compared with nondiabetic
Nox4+/+ApoE2/2 mice. In diabetic Nox42/2ApoE2/2 mice,
the development of glomerulosclerosis and the degree of me-
sangial expansion were significantly attenuated compared
with diabeticNox4+/+ApoE2/2mice after 20 weeks of diabetes
(Figure 2, A and B). These renoprotective structural changes
were not observed in diabetic Nox12/yApoE2/2 mice com-
pared with diabetic Nox1+/yApoE2/2 mice (Figure 2, C and D).
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Treatment of diabetic ApoE2/2 mice with the Nox inhibitor
GKT137831 for 20 weeks was also associated with attenuation
of glomerular injury, as assessed by the glomerulosclerosis in-
dex (Figure 2E) and mesangial area (Figure 2F). These results
suggest that genetic deletion of Nox4 and Nox inhibition with
GKT137831 in diabetic ApoE2/2 mice confer renoprotective
effects with respect to structural parameters. No such effect was
seen with deletion of Nox1. Furthermore, there was an increase
in the tubulointerstitial area in diabetic ApoE2/2 mice (Supple-
mental Figure 1). Indeed, the Nox inhibitor, GKT137831, sig-
nificantly attenuated the tubulointerstitial area (Supplemental
Figure 1, C and D). There was a similar trend seen in diabetic
Nox42/2ApoE2/2 mice (P=0.07) (Supplemental Figure 1, A
and B).
Nox4 Expression
Induction of diabetes was associated with
increased gene expressionofNox4 aswell as
Nox1 and Nox2 in renal cortex (Supple-
mental Figure 2A). In addition, Nox4
gene expression was also increased in the
tubular fraction of the renal cortex of di-
abetic mice (Supplemental Figure 2C).
Furthermore, there was an increase in
both glomerular and tubular Nox4 protein
expression, as assessed by immunofluores-
cence (Supplemental Figure 2, B andD). By
contrast, there was no significant Nox4 ex-
pression in the Nox4 KO mice in the ab-
sence or presence of diabetes.
Extracellular Matrix Proteins
We next examined glomerular collagen IV
and fibronectin accumulation, which are
known to be associated with glomerulo-
sclerosis and mesangial expansion in
diabetic nephropathy. Consistent with the findings on glo-
merulosclerosis and mesangial expansion, collagen IV protein
accumulationwas significantly increased in the glomeruli after
20 weeks of diabetes in Nox4+/+ApoE2/2 mice compared with
nondiabetic Nox4+/+ApoE2/2 controls. Importantly, the in-
crease in collagen IV expression was attenuated in Nox42/2
ApoE2/2 mice (Figure 3A). In contrast, this reduction in col-
lagen IV expression was not observed in Nox12/yApoE2/2
mice compared with diabetic Nox1+/yApoE2/2 mice (Figure
3B). Furthermore, Nox inhibition with GKT137831 in dia-
betic ApoE2/2 mice for 20 weeks was associated with a signif-
icant attenuation of the diabetes-induced increased expression
of collagen IV (Figure 3C). Similarly, fibronectin protein ac-
cumulation was increased in the glomeruli of mice after 20
Table 1. General andmetabolic parameters after 20 weeks of study in control and diabeticNox4+/+ApoE2/2 andNox42/2ApoE2/2
mice and in control and diabetic Nox1+/yApoE2/2 and Nox12/y ApoE2/2 mice (n=8–15 per group)
Parameter
Nox4 Deletion Nox1 Deletion
Nox4+/+ApoE2/2 Nox42/2ApoE2/2 Nox1+/yApoE2/2 Nox12/yApoE2/2
Control Diabetes Control Diabetes Control Diabetes Control Diabetes
Body weight (g) 3360.6 2260.9a 3160.6 2560.8a 3261 2361a 3461 2561a
Kidney weight/body
weight (%)
0.6160.01 0.9460.05a 0.6160.02 0.8260.01a 0.6260.02 0.8760.05a 0.5860.01 0.9060.02a
Systolic BP (mmHg) 9162.7 11067.0 9365.4 9964.7 10464 10664 10063 10162
Plasma glucose (mmol/L) 10.460.6 25.062.2a 11.260.6 24.361.3a 13.160.9 26.262.3a 12.760.4 29.661.4a
Glycated hemoglobin (%) 4.960.3 15.460.9a 7.860.9b 18.961.2a 4.860.4 18 0.961.5a 4.660.3 18.761.8a
Total cholesterol (mmol/L) 5.861.2 13.761.8a 8.260.4 16.361.8a 7.660.6 10.361.0a 7.360.6 14.461.7a,c
Triglycerides (mmol/L) 1.260.2 3.460.5a 0.860.1 5.060.9a 1.060.1 2.360.5a 1.260.2 3.760.6a
HDL (mmol/L) 1.260.3 2.560.5a 1.960.1 2.360.4 1.760.2 1.560.2 1.760.2 2.860.3a,c
LDL (mmol/L) 4.060.8 9.761.2a 5.960.3 11.761.2a 5.460.5 6.961.0a 5.060.4 10.061.2a
Data are the mean6SEM.
aP,0.05 versus respective control Nox4+/+ApoE2/2 or Nox42/2ApoE2/2 or control Nox1+/yApoE2/2 and Nox12/yApoE2/2 mice.
bP,0.05 versus control Nox4+/+ApoE2/2 mice.
cP,0.05 versus diabetic Nox1+/yApoE2/2 mice.
Table 2. General and metabolic parameters after 20 weeks of study in control





Control Diabetes Control Diabetes
Body weight (g) 3160.5 2560.7a 2860.6 2460.9a
Kidney weight/body
weight (%)
0.6060.01 0.9560.05a 0.5860.01 0.7760.03a,b
Systolic BP (mmHg) 10563.0 11364.7 10763.4 9866.3
Plasma glucose (mmol/L) 11.860.4 24.861.0a 13.660.5 28.961.5a
Glycated hemoglobin (%) 5.060.3 17.460.9a 560.07 15.761.6a
Total cholesterol (mmol/L) 6.760.5 13.361.9a 7.660.8 11.461.2a
Triglycerides (mmol/L) 1.260.1 3.260.7a 1.260.3 2.360.5a
HDL (mmol/L) 1.660.2 2.060.3 1.760.3 1.960.2
LDL (mmol/L) 4.660.3 9.861.4a 5.460.5 8.460.9a
Data are the mean6SEM.
aP,0.05 versus respective control ApoE2/2 and ApoE2/2 plus GKT137831.
bP,0.05 versus diabetic ApoE2/2 mice.
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weeks of diabetes, and this was prevented inmicewith deletion
of Nox4 (Figure 4A) but not with deletion of Nox1 (Figure
4B). Again, GKT137831 treatment of diabetic ApoE2/2 mice
for 20 weeks resulted in attenuated diabetes-induced increased
expression of fibronectin (Figure 4C).
We previously showed that renal vascular endothelial
growth factor (VEGF) expression is increased in experimental
diabetes and is associated with albuminuria.23 Indeed, we ob-
served that VEGF expression was higher in the glomeruli of
diabetic Nox4+/+ApoE2/2 mice compared with nondiabetic
controls, and this was attenuated in diabetic Nox42/2ApoE2/2
mice (Figure 5A). Furthermore, GKT137831 treatment of
diabetic ApoE2/2 mice for 20 weeks was also associated
with decreased expression of VEGF in the glomeruli of diabetic
ApoE2/2 mice (Figure 5B).
Together, these results suggest that genetic deletion ofNox4,
but not of Nox1, protects mice from renal functional and
structural changes associated with diabetic nephropathy via
Figure 1. Genetic deficiency of Nox4, but not of Nox1, and pharmacologic Nox inhibition attenuate diabetes-induced increased
albuminuria in diabetic ApoE2/2 mice. Urinary albumin excretion (A–C) and ACR (D–F) in control and diabetic Nox4+/+ApoE2/2 and
Nox42/2ApoE2/2 mice (A and D), control and diabetic Nox1+/yApoE2/2 and Nox12/yApoE2/2 mice (B and E), or control and diabetic
ApoE2/2 mice with and without treatment with GKT137831 (C and F) for 10 and 20 weeks (n=10–15 per group). Data are the
mean6SEM. *P,0.01 versus respective control Nox4+/+ApoE2/2 and Nox42/2ApoE2/2 mice (A and D), control Nox1+/yApoE2/2 and
Nox12/yApoE2/2 mice (B and E), or control ApoE2/2 and ApoE2/2 plus GKT137831 mice (C and F); #P,0.05 versus diabeticNox4+/+ApoE2/2
(A and D) or diabetic ApoE2/2 mice (C and F). ACR, albumin/creatinine ratio; Cont, control; Diab, diabetes; GKT, GKT137831.
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effects on glomerulosclerosis, mesangial expansion, collagen IV,
and fibronectin accumulation. Treatment of diabetic ApoE2/2
mice with the specific Nox inhibitor GKT137831 for 20 weeks
resulted in similar renoprotection as observed inNox4-deficient
ApoE2/2 mice, which provides a proof of concept for Nox in-
hibition as a novel therapeutic strategy for diabetic nephropathy.
Renal Superoxide and ROS Levels
There is increasing evidence that renal injury in diabetes is
associated with increased formation of ROS.2,4–6 Indeed,
nitrotyrosine, a marker of nitrative and oxidative stress, was
increased in glomeruli after 20 weeks of diabetes in Nox4+/+
ApoE2/2 and ApoE2/2 mice. Importantly, diabetic Nox42/2
ApoE2/2 mice and GKT137831-treated diabetic ApoE2/2
mice showed reduced nitrotyrosine accumulation in the
glomeruli compared with diabetic Nox4+/+ApoE2/2 and non-
treated diabetic ApoE2/2mice, respectively (Figure 6, A and C).
In line with our above-described observations, no reduction of
nitrotyrosine was observed in diabetic Nox12/yApoE2/2 mice
compared with diabetic Nox1+/yApoE2/2 mice (Figure 6B).
We alsomeasured superoxide generation in the renal cortex
using the dihydroethidium/HPLCmethod (Figure 7, A, C, and
Figure 2. Genetic deficiency of Nox4, but not of Nox1, and pharmacologic Nox inhibition attenuate glomerular injury in diabetic
ApoE2/2 mice. Glomerulosclerosis index (A) and mesangial area expansion (B) in control and diabeticNox4+/+ApoE2/2 andNox42/2ApoE2/2
mice after 20 weeks (n=7–8 per group). Glomerulosclerosis index (C) and mesangial area expansion (D) in control and diabeticNox1+/yApoE2/2
and Nox12/yApoE2/2 mice after 20 weeks (n=7–8 per group). Glomerulosclerosis index (E) and mesangial area expansion (F) in control and
diabetic ApoE2/2 mice with and without treatment with GKT137831 for 20 weeks (n=7–8 per group). Data are the mean6SEM. *P,0.01 versus
respective control Nox4+/+ApoE2/2 and Nox42/2ApoE2/2 mice (A and B), control Nox1+/yApoE2/2 and Nox1-/yApoE2/2 mice (C and D), or
control ApoE2/2 and ApoE2/2 plus GKT137831 mice (E and F); #P,0.05 versus diabeticNox4+/+ApoE2/2 (A and B) or diabetic ApoE2/2 mice
(E and F). Cont, control; Diab, diabetes; GKT, GKT137831.
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E)14,24 as well as ROS levels in the cytosolic andmitochondrial
fractions of the renal cortex using L-012–derived chemilumi-
nescence (Figure 7, B, D, and F). Diabetes was associated with
increased renal superoxide levels in the renal cortex (Figure 7,
A, C, and E). In addition, diabetes was associated with in-
creased ROS levels in both the cytosolic and mitochondrial
compartments (Figure 7, B, D, and F). Diabetic ApoE2/2mice
with genetic Nox4 deficiency did not show the diabetes-
induced increase in superoxide (Figure 7A) or ROS formation
in either intracellular compartment (Figure 7B). Similar re-
sults were obtained in diabetic ApoE2/2 mice treated with
GKT137831 for 20 weeks (Figure 7, E and F). Again, this effect
on reducing superoxide and ROS levels was not seen in Nox1-
deficient diabetic mice (Nox12/yApoE2/2 mice) (Figure 7, C
and D). These results suggest that renoprotection observed
with Nox4 deletion and pharmacologic Nox inhibition is
associated with reduced renal ROS formation. The results fur-
ther support the view that Nox4, but not Nox1, is a patholog-
ically relevant source of ROS in diabetic nephropathy.
Macrophage Infiltration
Diabetes is associated with recruitment and retention of
macrophages in glomeruli.25 Accordingly, expression of the
macrophage marker F4/80 in glomeruli of diabetic mice after
20 weeks of diabetes was increased in diabetic Nox4+/+ApoE2/2
andApoE2/2mice comparedwith their nondiabetic controls. Again,
this parameter was attenuated in diabetic Nox42/2ApoE2/2 mice
(Figure 8A) and in diabetic ApoE2 /2 mice treated with
GKT137831 (Figure 8C). In contrast, expression of F4/80 in
glomeruli of diabetic Nox12/yApoE2/2 mice was not different
from diabetic Nox1+/yApoE2/2 mice (Figure 8B).
Human Podocyte In Vitro Studies
Podocytes are considered to be centrally involved in regulation of
the glomerular filtration barrier and development of protein-
uria.26 We therefore investigated the effects of hyperglycemia
and TGF-b1, which are both key features of the diabetic milieu,
on ROS formation and markers of diabetes-related injury in a
human differentiated podocyte cell line as previously described
(Supplemental Figure 3).27 Under nonpermissive conditions,
the podocytes undergo growth arrest, display the typical arbor-
ized pattern of foot process extensions, and express markers of
mature podocytic differentiation including nephrin, synaptopodin,
and Wilms’ tumor-1 (Supplemental Figure 4).
Incubationofhumanpodocytes inhighglucose–containing
medium (25 mM, i.e., similar glucose concentrations to those
Figure 3. Genetic deficiency of Nox4, but not of Nox1, and pharmacologic Nox inhibition attenuate increased collagen IV accumulation
in glomeruli of diabetic ApoE2/2 mice. Immunostaining for collagen IV in glomeruli of control and diabetic Nox4+/+ApoE2/2 and
Nox42/2ApoE2/2 mice after 20 weeks (A), control and diabetic Nox1+/yApoE2/2 and Nox12/yApoE2/2 mice after 20 weeks (B), or
control and diabetic ApoE2/2 mice with and without treatment with GKT137831 for 20 weeks (C) (n=6–8 per group). Data are the
mean6SEM. *P,0.05 versus respective control Nox4+/+ApoE2/2 and Nox42/2ApoE2/2 mice (A), control Nox1+/yApoE2/2 and
Nox12/yApoE2/2 mice (B), or control ApoE2/2 and ApoE2/2 plus GKT137831 mice (C); #P,0.05 versus diabetic Nox4+/+ApoE2/2 (A)
or diabetic ApoE2/2 mice (C). Cont, control; Diab, diabetes; GKT, GKT137831.
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observed in the serum of our streptozotocin-treated mice)
resulted in increased mRNA levels of Nox4 (Figure 9A). The
addition of TGF-b to this hyperglycemic milieu further am-
plified the increase in Nox4 gene expression and to a lesser
extent also increased Nox5, but not Nox1, Nox2, or their cyto-
solic regulator, p47phox. The iso-osmotic control mannitol did
not result in changes in any Nox isoform levels (Figure 9A).
Furthermore, Nox4 protein was expressed in these podocytes,
as assessed by immunofluorescence (Supplemental Figure 5).
We next infected human podocytes with a lentiviral Nox4
short hairpin RNA (shRNA) expression construct. This
resulted in a decrease in Nox4 gene expression of approxi-
mately 70% (Supplemental Figure 6). Nox4 shRNA treatment
of the podocytes did not change the mRNA levels of Nox1,
Nox2, or Nox5 (Supplemental Figure 6). Importantly, the high
glucose– and TGF-b1–induced increase in ROS production
was reduced in Nox4 knockdown cells to ROS levels seen in
podocytes in normal glucose or in cells that had not been
treated with TGF-b1 (Figure 9, B and D).
High glucose alone increased the gene expression of the
extracellular matrix (ECM) proteins, collagen IV, and fibro-
nectin as well as VEGF, whereas the effect ona-smoothmuscle
actin (a-SMA) did not reach statistical significance (Figure
9C). The addition of TGF-b significantly increased gene ex-
pression of collagen IV, fibronectin, VEGF, and a-SMA (Fig-
ure 9E). Silencing of Nox4 by infecting the podocytes with a
Nox4 shRNA led to a decrease in both the glucose– and TGF-
b–induced increased expression of collagen IV, fibronectin,
VEGF, and a-SMA compared with cells infected with nontar-
geted control constructs (Figure 9, C and E).
TGF-b– and high glucose–induced upregulation of Nox4
with an associated increase in ROS formation was attenuated
by pretreatment of human podocytes with the Nox inhibitor
GKT137831 (Figure 10A). Furthermore, the increased expres-
sion of collagen IV, fibronectin, connective tissue growth fac-
tor, VEGF, and a-SMA as a result of high glucose and TGF-b
were significantly attenuated when cells were pretreated with
GKT137831 (Figure 10B).
Inflammatory Parameters: Monocyte Chemoattractant
Protein-1 and NF-kB
We further investigated the effect of Nox4 deletion on the NF-
kB/monocyte chemoattractant protein-1 (MCP-1) axis, a
pathway that has been implicated in the development of di-
abetic nephropathy.25 Consistent with the results observed
with respect tomacrophage infiltration into the kidney (Figure
Figure 4. Genetic deficiency of Nox4, but not of Nox1, and pharmacologic Nox inhibition attenuate increased fibronectin accumulation
in glomeruli of diabetic ApoE2/2 mice. Immunostaining for fibronectin in glomeruli of control and diabetic Nox4+/+ApoE2/2 and
Nox42/2ApoE2/2 mice after 20 weeks (A), control and diabetic Nox1+/yApoE2/2 and Nox12/yApoE2/2 mice after 20 weeks (B), or
control and diabetic ApoE2/2 mice with and without treatment with GKT137831 for 20 weeks (C) (n=6–8 per group). Data are the
mean6SEM. *P,0.05 versus respective control Nox4+/+ApoE2/2 and Nox42/2ApoE2/2 mice (A), control Nox1+/yApoE2/2 and Nox1-/y
ApoE2/2 mice (B), or control ApoE2/2 and ApoE2/2 plus GKT137831 mice (C); #P,0.05 versus diabetic Nox4+/+ApoE2/2 (A) or diabetic
ApoE2/2 mice (C). Cont, control; Diab, diabetes; GKT, GKT137831.
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8), we observed upregulation of the MCP-1 gene in the renal
cortex of diabeticmice, whichwas significantly attenuated in the
diabetic Nox4-deficient mice (Figure 11C). There was also a
trend toward a decrease in the diabetes-induced upregulation
of the NF-kB subunit p65 in the renal cortex of Nox4 KO mice
(Figure 11D). To complement these in vivo findings, in vitro
studies were performed in human podocytes. Indeed, silencing
of Nox4 abrogated the high glucose–induced upregulation of
MCP-1 and p65 mRNA levels (Figure 11, A and B).
In addition, expression of MCP-1 in protein extracts of
renal cortex after 20weeks of diabetes was increased in diabetic
Nox4+/+ApoE2/2 and ApoE2/2 mice compared with their
nondiabetic controls. Again, this parameter was attenuated
in diabetic Nox42/2ApoE2/2 mice (Figure 11E) and in diabetic
ApoE2/2mice treatedwithGKT137831 (Figure 11G). In contrast,
MCP-1 protein in renal cortex of diabeticNox12/yApoE2/mice
was not different from diabetic Nox1+/yApoE2/2 mice (Figure
11F).
DISCUSSION
This study provides evidence thatNox4-derived, but notNox1-
derived, ROS are causatively linked to the development and
progression of diabetic nephropathy. This
evidence is based on the first direct compar-
ison of Nox4 or Nox1 deletion in ApoE2/2
mice. We used ApoE2/2 mice because strep-
tozotocin-induced diabetes in ApoE2/2mice
is a well characterized model of advanced
renal injury with prominent ECM ac-
cumulation.28,29 Importantly, we translated
these findings into a potential clinical ther-
apy by showing that Nox inhibition in
diabetic ApoE2/2 mice using a pharmaco-
logic strategy resulted in a similar degree
of renoprotection to that observed with
deletion of Nox4.
Previous studieshave already suggested a
role for Nox-derived ROS in the develop-
ment and progression of diabetic nephrop-
athy but these experiments were short term
and/or investigated only a single Nox iso-
form.4–6,19 With respect to pharmacologic
intervention, previous studies relied on
nonspecific inhibitors of ROS formation,
such as apocynin, a drug that has also
been reported to interfere with Rho ki-
nase.30,31 Therefore, we postulate that this
longer-term study is potentially more rele-
vant with respect to clinical target valida-
tion.
In this study, we were able to combine
observations of a renoprotective effect of
genetically deleting Nox4 with pharmaco-
logic inhibition of Nox using the most specific compound
currently available, GKT137831. In diabetic ApoE2/2 mice,
Nox4 deletion or treatment with GKT137831 attenuated var-
ious parameters of glomerular injury, including albuminuria,
and glomerular structural changes, including ECM accumu-
lation. Furthermore, the diabetes-induced increase in tubu-
lointerstitial area was significantly attenuated using the novel
Nox inhibitor GKT137831. In addition, macrophage infiltra-
tion was reduced in diabetic Nox4 KOmice and these changes
occurred in association with attenuation of the expression of
the chemokine MCP-1 and the key proinflammatory tran-
scription factor, NF-kB. In addition, these renoprotective ef-
fects were associated with reduced renal cortical superoxide
generation and a decrease in both cytosolic andmitochondrial
ROS levels as well as reduced nitrotyrosine accumulation
within glomeruli. In contrast, genetic deletion of Nox1 in
ApoE2/2 mice did not attenuate renal ROS generation and
failed to prevent glomerular injury in diabetic mice.
Consistent with other studies using type 1 and type 2
diabetic models,11,12,32 we observed increased Nox4 mRNA
in the renal cortex of diabetic mice. One must exert due cau-
tion in interpreting results with respect to Nox4 protein
expression because there is currently no fully validated
monospecific Nox4 antibody available. In the context of
Figure 5. Genetic deficiency of Nox4 and pharmacologic Nox inhibition attenuate
increased VEGF expression in glomeruli of diabetic ApoE2/2 mice. Immunostaining for
VEGF in glomeruli of control and diabetic Nox4+/+ApoE2/2 and Nox42/2ApoE2/2
mice after 20 weeks (A) and control and diabetic ApoE2/2 mice with and without
treatment with GKT137831 for 20 weeks (B) (n=6–8 per group). Data are the
mean6SEM. *P,0.05 versus respective control Nox4+/+ApoE2/2 and Nox42/2
ApoE2/2 mice (A) or control ApoE2/2 and ApoE2/2 plus GKT137831 mice (B);
#P,0.05 versus diabetic Nox4+/+ApoE2/2 (A); ‡P=0.08 versus diabetic ApoE2/2 mice
(B). Cont, control; Diab, diabetes; GKT, GKT137831.
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these limitations, we identified increased immunoreactivity
to Nox4 in diabetic ApoE2 /2 mice, particularly in the
glomerulus, a phenomenon not observed in Nox4 KO
mice. These findings are similar to those reported in
shorter-term studies by other groups.19
A previous study by Gorin et al. suggested that short-term
downregulation of Nox4 by systemic administration of antisense
oligonucleotides attenuated renal and glomerular hypertrophy as
well as reduced the increase in fibronectin expression that is
commonly seen in the diabetic kidney.19 This group has recently
further explored the link between Nox4 and ECM production
and has shown that Nox4 can bemodulated by thematrixmetal-
loproteinase, ADAM (a disintegrin and metalloproteinase)-17.33
Babelova et al.20 investigated the role of Nox4 in various
models of renal injury, including a model of streptozotocin-
induced diabetes, albeit in C57BL/6 and not in ApoE2/2mice.
Consequently, and in contrast to our findings, those authors
did not observe upregulation of Nox420 and Nox4 deficiency
did not attenuate nephropathy. However, C57BL/6 mice are
relatively resistant to the development of typical morphologic
features of diabetic nephropathy.34 These differences in the
duration of the experimental model and the mouse strains
utilized may explain the conflicting results of that study with
our and other studies.11,19,32
Given the importance of podocytes not only in albuminuria
but also in morphologic manifestations of diabetic nephrop-
athy, and to translate our findings from mice to a human
context, we performed in vitro studies using human podo-
cytes. In line with the in vivo observations using mice, Nox4
and to a lesser extent Nox5 were upregulated in response to
high glucose and this upregulationwas further amplified in the
presence of TGF-b1 exposure, both key features of the diabetic
milieu.35,36 Both silencing of Nox4 and Nox inhibition with
GKT137831 reduced ROS levels in human podocytes, and this
was associated with attenuation of critical pathways linked to
renal fibrosis, including gene expression of collagen IV, fibro-
nectin, connective tissue growth factor, and a-SMA. These
findings confirm a previous report in which Nox4 was shown
to play an important role in hyperglycemia-induced ROS for-
mation inmouse podocytes37; however, our study importantly
confirms and extends these findings to human cells and em-
phasizes the effect of Nox4 on prosclerotic pathways.
The effects of Nox4-derived ROS formation on VEGF
expression, a growth factor expressed by renal cells including
Figure 6. Genetic deficiency of Nox4, but not of Nox1, and pharmacologic Nox inhibition attenuate nitrotyrosine accumulation in
glomeruli of diabetic ApoE2/2 mice. Immunostaining for nitrotyrosine in glomeruli of control and diabetic Nox4+/+ApoE2/2 and
Nox42/2ApoE2/2 mice after 20 weeks (A), control and diabetic Nox1+/yApoE2/2 and Nox12/yApoE2/2 mice after 20 weeks (B), or
control and diabetic ApoE2/2 mice with and without treatment with GKT137831 for 20 weeks (C) (n=6–8 per group). Results are
expressed relative to control Nox4+/+ApoE2/2 mice (A), control Nox1+/yApoE2/2 mice (B), or control (untreated) ApoE2/2 mice (C),
which were arbitrarily assigned a value of 1. Data are the mean6SEM. *P,0.05 versus respective control Nox4+/+ApoE2/2 and Nox42/2
ApoE2/2 mice (A), control Nox1+/yApoE2/2 and Nox12/yApoE2/2 mice (B), or control ApoE2/2 and ApoE2/2 plus GKT137831 mice
(C); #P,0.05 versus diabetic Nox4+/+ApoE2/2 (A) or diabetic ApoE2/2 mice (C). Cont, control; Diab, diabetes; GKT, GKT137831.
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Figure 7. Genetic deficiency of Nox4, but not of Nox1, and pharmacologic Nox inhibition attenuate increased renal superoxide and
ROS formation in diabetic ApoE2/2 mice. Superoxide production in renal cortex (A, C, and E) and ROS production in cytosolic and
mitochondrial fractions of the renal cortex (B, D, and F) in control and diabetic Nox4+/+ApoE2/2 and Nox42/2ApoE2/2 mice (A and B),
control and diabetic Nox1+/yApoE2/2 and Nox12/yApoE2/2 mice after 20 weeks (C and D), or control and diabetic ApoE2/2 mice with
and without treatment with GKT137831 for 20 weeks (E and F) (n=5–6 per group). Superoxide data (A, C, and E) are shown as the ratio
of 2HE (nanomoles) to DHE (micromoles). With respect to ROS measurements, results were expressed relative to control Nox4+/+
ApoE2/2 mice (B), control Nox1+/yApoE2/2 mice (D), or control (untreated) ApoE2/2 mice (F), which was arbitrarily assigned a value of
100. Data are the mean6SEM. *P#0.05 versus respective control Nox4+/+ApoE2/2 or control Nox1+/yApoE2/2 mice or control ApoE2/2
mice; #P,0.05 versus diabetic Nox4+/+ApoE2/2 or diabetic ApoE2/2 mice. 2HE, 2 hydroethidium; Cont, control; Diab, diabetes; DHE,
dihydroethidium; GKT, GKT137831; RLU, relative light unit.
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podocytes,38 were also confirmed by our in vivo studies of
diabetic nephropathy. Both Nox4 deletion and inhibition of
Nox with GKT137831 were associated with attenuation of the
diabetes-induced increase in VEGF expression in glomeruli,
and this was also associated with reduced proteinuria. Fur-
thermore, in our in vitro studies, GKT137831 treatment at-
tenuated podocyte VEGF expression in a hyperglycemic
milieu. Importantly, this is likely to be Nox4 dependent be-
cause downregulation of Nox4 in human podocytes was also
associated with attenuation of VEGF expression. Consistent
with our findings, other researchers reported a link between
VEGF with Nox4 in the retina, where Nox4 was associated
with vascular permeability,39 as well as similar findings in a
stroke model.40
Diabetic nephropathy is considered to be at least in part an
inflammatory disorder inwhich progressive glomerular injury
is associated with macrophage infiltration.25 Consistent with
this view, induction of diabetes in our study was associated
with a significant increase in accumulation of macrophages
within the glomeruli. These changes were attenuated in dia-
betic Nox4-deficient mice and in diabetic ApoE2/2mice treated
with the Nox inhibitor GKT137831 but not in diabeticNox12/y
mice. A link between Nox4 and inflammation was previously
suggested, albeit in a nonrenal context. Specifically, Nox4
downregulation using a small interfering RNA approach atten-
uated the LPS-induced proinflammatory response in human
endothelial cells.41 Consistent with these effects of Nox4 de-
letion on renal macrophage infiltration, we observed reduced
expression of the key proinflammatory transcription factor
NF-kB as well as the well characterized NF-kB–dependent
chemokine MCP-1 on the gene and protein level in the renal
cortex. Complementary in vitro studies in human podocytes
confirmed that high glucose–induced upregulation of the
NF-kB subunit, p65, and MCP-1 could be prevented by silenc-
ing of Nox4.
Block et al. suggested that Nox4 is present in the mitochon-
dria, and that silencing of mitochondrial Nox4 is associated
with reduced mitochondrial oxidative stress and injury.15
Thus, we examined ROS formation in not only the cytosolic
fraction but also in the mitochondrial fraction of the renal
cortex. Indeed, we demonstrated reduced mitochondrial as
well as cytosolic ROS generation in the renal cortex of diabetic
Nox4-deficientmice. GKT137831 treatment of diabeticApoE2/2
mice caused similar reductions in mitochondrial ROS
Figure 8. Genetic deficiency of Nox4, but not of Nox1, and pharmacologic Nox inhibition attenuates macrophage infiltration in
glomeruli of diabetic ApoE2/2 mice. Immunostaining for F4/80 in glomeruli of control and diabetic Nox4+/+ApoE2/2 and Nox42/2
ApoE2/2 mice (A) or in control and diabetic Nox1+/yApoE2/2 and Nox12/yApoE2/2 mice after 20 weeks (B), or control and diabetic
ApoE2/2 mice with and without treatment with GKT137831 for 20 weeks (C) (n=6–8 per group). Data are the mean6SEM. *P,0.05
versus respective control Nox4+/+ApoE2/2 and Nox42/2ApoE2/2 mice (A), control Nox1+/yApoE2/2 and Nox1-/yApoE2/2 mice (B), or
control ApoE2/2 and ApoE2/2 plus GKT137831 mice (C); #P,0.05 versus diabetic Nox4+/+ApoE2/2 (A) or diabetic ApoE2/2 mice (C).
Cont, control; Diab, diabetes; GKT, GKT137831.
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Figure 9. Silencing of Nox4 attenuates high glucose–as well as high glucose plus TGF-b1–mediated ROS formation and gene expression of
profibrotic markers in human podocytes. (A) Nox4 and Nox5, but not Nox1, Nox2, or p47phox mRNA levels were upregulated in human
podocytes by diabetic stimuli. Analysis of Nox isoform mRNA levels and the cytosolic regulator, p47phox, in cultured differentiated human
podocytes in NG (5 mM) or HG (25 mM) and in the presence or absence of TGF-b1 (5 ng/ml, 2 days). Mannitol (20 mM/L+5 mM D-glucose)
served as an osmotic control. Data are the mean6SEM. *P,0.05 versus NG; #P,0.05 versus HG. (B and C) Analysis of ROS production (B) and
RT-PCR (C) for collagen IV, fibronectin, VEGF and a-SMA in differentiated human podocytes transfected with shRNA specific for Nox4 and then
grown in NG (5 mM) or HG (25 mM) for 2 days (B and C). Results for ROS production are expressed relative to nontarget plus NG, which was
arbitrarily assigned a value of 100 (B). Data are the mean6SEM (n=6/group). ∧P,0.05 versus nontarget plus NG; §P,0.05 versus nontarget plus
HG. (D and E) Analysis of ROS production (D) and RT-PCR (E) for collagen IV, fibronectin, VEGF and a-SMA in differentiated human podocytes
transfected with shRNA specific for Nox4 and then grown in the presence or absence of TGF-b1 (5 ng/ml) for 4 hours for ROS production (D)
and 2days for RT-PCR (E). Data are the mean6SEM (n=6/group). †P,0.05 versus nontarget, ‡P,0.05 versus non-target plus TGF-b1. HG, high
glucose; NG, normal glucose; RLU, relative light unit.
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generation. These findings strengthen the view that Nox4 is not
only a cytosolic but also amitochondrial source of ROS, at least
in the diabetic kidney. Other groups have shown that altera-
tions in the electron transport chain are a major source of
mitochondrial ROS in the setting of hyperglycemia.42,43 How-
ever, our findings extend these results by demonstrating that
Nox4 may be an alternative or additional target to reduce mi-
tochondrial oxidative stress, particularly in the kidney.
The role of Nox1 in diabetic nephropathy has not been
clearly delineated previously. Nox1 is expressed in the renal
cortex, including in glomeruli of the normal kidney, albeit at
almost undetectable levels. Increased renal expression of Nox1
has been reported in hypertension-associated forms of renal
disease such as inmodels of angiotensin II infusion and inDahl
salt-sensitive hypertensive rats.44,45 These findings are relevant
because activation of the renin-angiotensin system in the di-
abetic kidney has been shown to promote renal injury.46,47
Angiotensin II induces upregulation of Nox1.48 Therefore, it
has been postulated that Nox1 could play an important role in
the development and progression of diabetic nephropathy.44,45
However, in our study, Nox1 deletionwas not associated with an
improvement in diabetes-related renal injury. Thus, ourfindings
argue against a critical role forNox1 in diabetic nephropathy but
Nox1may bemore important, as recently suggested, in diabetes-
associated macrovascular disease.49
We focused our study on Nox1 and Nox4 and did not
specifically address Nox2, which was previously shown to not
play a key role in diabetic nephropathy.50 Furthermore, Nox2
deletion was reported to be associated with increased suscep-
tibility to infections in the context of diabetes mellitus.14 Nev-
ertheless, one cannot exclude a potential role for partial Nox2
inhibition but the lethality of severe Nox2 deficiency in hyper-
glycemic states is likely to narrow the therapeutic window of
such an approach. There are also increasing data to suggest a
role for another Nox isoform, Nox5, in pathologic ROS gen-
eration.7,51 However, because Nox5 is not present in rats and
mice, we were not able to delineate the contribution of this
particular Nox isoform in our in vivomodels. Nevertheless, in
human podocytes, Nox5was upregulated upon treatment with
diabetes-related stimuli, such as high glucose and TGF-b1.
Thus, we cannot exclude an additional role for Nox5 in human
diabetic nephropathy.
To test thepossibility to clinically translate our experimental
studies, we administered GKT137831 to diabetic ApoE2/2
mice. This Nox inhibitor has been suggested to have dual ef-
ficacy on Nox1 and Nox4. It has been shown to provide end-
organ protective effects, albeit in the liver.22,52 Importantly, in
our study, treatment of diabetic ApoE2 /2 mice with
GKT137831mimicked the effects of Nox4 deletion on glomer-
ular injury, albuminuria, ROS production, ECM accumula-
tion, and macrophage infiltration. Thus, the renoprotective
effects of GKT137831 are likely to be mediated by Nox4 rather
than Nox1 inhibition. In line with our study results, another
Nox inhibitor, GKT136901, was recently reported to be reno-
protective in amodel of type 2 diabetes, the db/dbmouse. This
renoprotective effect was associated with reduced albuminuria
and urinary excretion of thiobarbituric acid–reactive substan-
ces as well as attenuation of renal extracellular signal-regulated
protein kinase 1/2 phosphorylation.8 The initial antialbumi-
nuric effect observed in that study was not sustained after 16
weeks of diabetes. It is possible that the longer lasting antial-
buminuric effect seen in our study may be related to a differ-
ence in potency between the two compounds or more likely
related to the mode of administration of the Nox inhibitor.
The drug was mixed in the food in the previous study,8
whereas the drug was administered by gavage in this study.
In conclusion, compelling evidence is provided that Nox4,
but not Nox1, is a major pathologic renal source of ROS in a
long-term model of insulin-deficient diabetes leading to
relatively advanced diabetic nephropathy. Our experiments
have identified Nox4 as an attractive mechanism-based ther-
apeutic target for the treatment of diabetic nephropathy.
Furthermore, we provide proof of principle that this mech-
anism can be translated into a novel pharmacologic therapy
with important future clinical implications. Therefore, our
study strengthens the need to developNox4-specific inhibitors




Diabetes-induced renal functional changes and morphologic kidney
damage were studied in diabeticNox4+/+ApoE2/2,Nox42/2ApoE2/2
doubleKO,Nox1+/yApoE2/2,Nox12/yApoE2/2doubleKO, andApoE2/2
male mice and compared with respective nondiabetic control mice.
Nox1+/yApoE2/ mice were generated as previously described.53,54 To
generate the double KO mice, Nox4 KO mice41 were crossed for 10
generations with the ApoE2/2 mouse strain (Animal Resources Cen-
tre, Murdoch, WA, Australia). Initially we mated ApoE2/2 (F) with
Nox42/2 (M) mice to produce heterozygotes in the F1 generation
(Nox4+/2ApoE+/2). From the F2 generation we set up Nox4+/2ApoE2/23
Nox42/2ApoE+/2 and Nox42/2ApoE+/2 3 Nox42/2ApoE2/2, which
produced the F3 generation including theWTNox4+/+ApoE2/2 and dou-
bleKONox42/2ApoE2/2mice. From that generation,wematedmale and
female Nox42/2 ApoE2/2 mice and are now at the 16th generation.
Diabeteswas induced in6-week-oldmicebyfivedaily intraperitoneal
injections of streptozotocin (Sigma-Aldrich, St Louis, MO), at a dose of
55 mg/kg in citrate buffer, with control mice receiving citrate buffer
alone. None of the animals with diabetes required supplemental insulin
tomaintainbodyweightor topreventketosis.Asubgroupofdiabetic and
nondiabetic ApoE2/2 mice were treated with the Nox inhibitor,
GKT137831, administered daily by gavage at a dose of 60 mg/kg per
day for 20 weeks commencing with the last injection of streptozotocin.
GKT137831, a member of the pyrazolopyridinedione family, is a spe-
cific inhibitor of both Nox4 and Nox1 isoforms (Ki in the range of 100–
150 nM in cell-free assays of ROSproduction). It has noROS scavenging
activity when tested at a concentration of 10 mM.52,55
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After 20 weeks, animals were anesthetized by sodium pentobar-
bitone intraperitoneally (100 mg/kg body weight) (Euthatal; Sigma-
Aldrich, Castle Hill, NSW, Australia). The kidneys were rapidly
dissected, weighed, and snap-frozen or processed to paraffin for
subsequent analysis. All animal studies were approved by the Alfred
Medical Research & Education Precinct Animal Ethics Committee
under guidelines of the National Health and Medical Research
Council of Australia. All animals were housed at the Precinct Animal
Centre of the Baker IDI Heart & Diabetes Institute. During the
study, animals had unrestricted access to water and food and were
maintained on a 12-hour light/dark cycle in a pathogen-free envi-
ronment on standard mouse chow (Specialty Feeds, Perth, WA,
Australia).
Measurement of Metabolic Parameters
At 10 and 20 weeks after induction of diabetes, mice were placed
individually intometabolic cages (Iffa Credo, L’Arbresele, France) for
24 hours. Urine was collected for subsequent analysis. Blood glucose
was measured serially using a glucometer (Accutrend; Boehringer
Manheim Biochemica, Manheim, Germany). Glycated hemoglobin
was measured by HPLC (CLC330 GHb Analyzer; Primus, Kansas
City, MO) in lysates of erythrocytes separated from whole blood.56
Systolic BP was assessed using a computerized noninvasive tail-cuff
method.57 Mice were familiarized with the equipment with readings
taken by an experienced technician in consciousmice at the end of the
20-week study. Urinary albumin concentration was measured at 10
and 20 weeks after the induction of diabetes, using a mouse albumin
ELISA quantitation kit (Bethyl Laboratories, Montgomery, TX).
Urinary creatinine concentrations were mea-
sured by HPLC as previously described.56,58
The urinary albumin/creatinine ratios were
calculated.
In Vivo Gene Expression Analyses
Total RNA was extracted after homogenizing
renal cortex (Polytron PT-MR2100; Kinema-
ticca, Littau/Lucerne, Switzerland) in TRIzol
reagent (Invitrogen Australia, Mt Waverly,
VIC, Australia) as previously described.56
Gene expression using probes and primers as
described in Supplemental Table 1 for Nox1,
Nox2, Nox4, MCP-1, and NF-kB p65 were an-
alyzed quantitatively and relative to the expres-
sion the housekeeping gene 18S (18S ribosomal
RNA TaqMan Control Reagent kit) using the
TaqMan system (ABI Prism 7500; PerkinElmer,
Poster City, CA).14,56 Results were expressed rel-
ative to nondiabetic ApoE2/2 mice, which were
arbitrarily assigned a value of 1.
Histologic Assessment
Three-micrometer kidney sections were stained
with periodic acid–Schiff for measurement of
glomerulosclerotic injury andmesangial expan-
sion. Mesangial area was analyzed (percentage
of glomerular area) from digital pictures of glomeruli (20 glomeruli
per kidney per animal) using Image-Pro plus 6.0 software (Media
Cybernetics, Bethesda, MD), as previously described.56,58 Glomeru-
losclerotic injury was graded based on the severity of glomerular
damage, including mesangial matrix expansion, hyalinosis with focal
adhesion, capillary dilation, glomerular tuft occlusion, and sclerosis,
as previously described.12,29,59 Twenty glomeruli per kidney were
assessed in a blinded fashion.
Immunohistochemistry
Renal paraffin sections (4-mm) were stained for collagen IV (1:600,
rabbit polyclonal anti-collagen IV; Abcam, Cambridge, MA), fibro-
nectin (1:800, polyclonal rabbit anti-fibronectin; Dako Cytomation,
Glostrup, Denmark), nitrotyrosine (1:100, rabbit polyclonal anti-
nitrotyrosine; Millipore, Billerica, MA), F4/80 (1:50, rat monoclonal
anti- F4/80; Abcam) and VEGF (mouse monoclonal anti-human
VEGF; Millipore, Upstate Biotechnology, Lake Placid, NY). Briefly,
sections were dewaxed, hydrated, and quenched with 3% H2O2 in
Tris-buffered saline (TBS) to inhibit endogenous peroxidase activity.
Sections for collagen IV and fibronectin were digested with 0.4%
pepsin (Sigma-Aldrich) in 0.01 M HCl at 37°C. This was followed
by incubation with 0.5% milk diluted in TBS to block nonspecific
binding. Subsequently, sections were incubated with the primary an-
tibody overnight at 4°C followed by avidin/biotin blocking. Sections
for nitrotyrosine were incubated with 10% normal horse serum in
TBS instead of 0.5% milk before incubation with the primary anti-
body. Similarly, sections for F4/80 were incubatedwith protein block-
ing agent (Dako CSA Kit) before incubation with the primary
Figure 10. Nox inhibition ameliorates TGF-b1–induced ROS generation and gene
expression of profibrotic markers in human podocytes. (A) Nox inhibition ameliorates
TGF-b1–induced ROS generation in human podocytes. Analysis of ROS production in
cultured differentiated human podocytes after pretreatment with and without
GKT137831 (10 mM) for 2 hours in the presence and absence of TGF-b1 (5 ng/ml) for 4
hours. DMSO serves as the vehicle control. Results are expressed relative to control,
which is arbitrarily assigned a value of 100. (B) Nox inhibition decreases the high
glucose– and TGF-b1–induced increased gene expression of collagen IV, fibronectin,
CTGF, VEGF, and a-SMA in human podocytes. The mRNA levels are quantified in
cultured differentiated human podocytes after pretreatment with and without
GKT137831 (10 mM) for 2 hours in the presence or absence of TGF-b1 (5 ng/ml) for 2
days. DMSO serves as the vehicle control. Data are the mean6SEM (n=6 per group).
*P,0.05 versus control; #P,0.05 versus TGF-b1. COL4, collagen IV; CTGF, connec-
tive tissue growth factor; GKT, GKT137831; RLU, relative light unit.
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antibody anti-F4/80 overnight at 4°C and staining was also amplified
further by Dako Catalyzed Signal Amplification Kit, according to the
manufacturer’s instructions. Thereafter, biotinylated anti-rabbit Ig
(1:500) for collagen IV, fibronectin, nitrotyrosine, and biotinylated
anti-rat Ig (1:200) for F4/80 (Vector Laboratories, Burlingame, CA)
were applied as the secondary antibody, followed by horseradish
peroxidase–conjugated streptavidin (VECTASTAIN Elite ABC Staining
Kit; Vector Laboratories). Peroxidase conjugates were subsequently
visualized using 3,39-diaminobenzidine tetrahydrochloride (Sigma-
Aldrich) in 0.08% H2O2/TBS. For VEGF immunostaining, a Dako
ARKPeroxidase forMouse Primary Antibodies protocolwas followed.
Sections were dewaxed, hydrated, and incubated with peroxidase
block followed by incubation with biotinylated primary anti-VEGF
antibody for 1 hour at room temperature and incubation with
streptavidin peroxidase. Peroxidase conjugates were subsequently vi-
sualized using 3,39-diaminobenzidine substrate chromogen.
Finally, sections were counterstained with Mayer’s hematoxylin,
dehydrated, and mounted. All sections were examined under a light
microscope (Olympus BX-50; Olympus Optical, Tokyo, Japan) and
digitized with a high-resolution camera. For the quantification of the
proportional area of staining, 20 glomeruli (3400) were analyzed
using Image-Pro plus 6 (Media Cybernetics).56,58 All assessments
were performed in a blinded manner. Six or eight kidneys were in-
vestigated in each group.
MCP-1 ELISA
The concentration of MCP-1 was identified in the protein extracts
obtained from the renal cortex for each group (n=5–6 per group) by
Figure 11. Genetic targeting of Nox4 attenuates diabetes-induced increased expression of proinflammatory markers MCP-1 and NF-kB
p65 in vitro and in vivo. (A and B) RT-PCR analysis of (A) MCP-1 and (B) NF-kB p65 in human podocytes transfected with shRNA specific
for Nox4 and then grown in NG (5 mM) or HG (25 mM) for 2 days. Data are the mean6SEM (n56/group). *P,0.05 versus nontarget
plus NG; #P,0.01 versus nontarget plus HG. (C and D) RT-PCR analysis of (C) MCP-1 and (D) NF-kB p65 in renal cortex of control and
diabetic Nox41/1ApoE2/2 and Nox42/2ApoE2/2 mice after 20 weeks. Data are the mean6SEM (n56/group). ^P,0.05 versus control
Nox41/1ApoE2/2; §P,0.05 versus diabetic Nox41/1ApoE2/2 mice. (E and F) Measurement of MCP-1 by ELISA in protein extracts of
renal cortex of (E) control and diabetic Nox41/1ApoE2/2 and Nox42/2ApoE2/2 mice or in (F) control and diabetic Nox11/yApoE2/2
and Nox12/yApoE2/2 mice after 20 weeks, (n55–6/group) or in (G) control and diabetic ApoE2/2 mice with and without treatment with
GKT137831 for 20 weeks, (n55–6/group). Data are the mean6SEM. †P,0.05 versus respective controlNox41/1ApoE2/2 andNox42/2ApoE2/2
mice (E) or control Nox11/yApoE2/2 and Nox12/yApoE2/2 mice (F) or control ApoE2/2 and ApoE2/2 plus GKT137831 mice (G);
‡P,0.05 versus diabetic ApoE2/2 mice (G). Cont, control; Diab, diabetes; GKT, GKT137831; HG, high glucose; NG, normal glucose.
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using the instructions of an ELISA kit (1:3; R&D Systems, Kirrawee,
NSW, Australia). The ELISA results were expressed relative to the
protein concentration.
Measurements of Superoxide and ROS Production in
Renal Cortex
Renal superoxide levels were measured in frozen kidney cortex using
HPLC calibrated to measure dihydroethidium by a previously
established method.14,24 Furthermore, ROS levels were measured in
frozen kidney cortex. Briefly, renal cortex was homogenized in Krebs
buffer, and cytosolic and mitochondrial fractions were prepared by
differential centrifugation as previously described.24 Cytosolic and
mitochondrial isolates were assayed in duplicate in clear 96-well
plates and prewarmed Krebs-HEPES supplemented with L-012
(Wako Chemicals, Richmond, VA) at a concentration of 100 mM
added to each well in the dark and incubated at 37°C for 10 minutes.
After incubation, plates were read in a luminometer (MicroLumat
Plus; Berthold Technologies, Pforzheim, Germany) and lumines-
cence was measured with a single measuring time of 1 second and
cycle time of 111 seconds for 20 minutes at 37°C. Buffer blank was
subtracted from each reading. A bicinchoninic acid protein assay
(Pierce/Thermo Scientific, Scoresby, VIC, Australia) was performed
(samples 1:10 in PBS) according to the kit instructions and results
were expressed relative to the total protein concentration (in milli-
grams).
In Vitro Experiments
Conditionally immortalized human podocytes were used for the in
vitro study.60 Podocytes were grown in RPMI with 10% FCS and 13
ITS media supplement (Sigma-Aldrich), which contains 1.0 mg/ml
insulin from bovine pancreas, 0.55mg/ml human transferrin, and 0.5
mg/ml sodium selenite in a humidified incubator, 5% CO2 at 33°C.
Approximately 60% confluent cells were transferred to 2%FBSmedia
and incubated at 37°C for 2 weeks.27 Under these conditions, the
podocytes undergo growth arrest, display the typical arborized pat-
tern of foot process extensions (Supplemental Figure 3), and express
markers ofmature podocytic differentiation in vivo, includingWilms’
tumor-1 and nephrin (Supplemental Figure 4). Cells were then cul-
tured in RPMI with 5 mmol/L glucose or 25 mmol/L glucose in the
presence or absence of TGF-b1 (5 ng/ml; R&D Systems,Minneapolis,
MN) with or without GKT137831 (10mM) dissolved in 0.1%DMSO
and incubated for 48 hours at 37°C.
shRNA to Nox4
The knockdown of Nox4 was performed in human podocyte using
MISSION shRNA expressing lentivirus vectors (Sigma-Aldrich) as
previously described.61 The sequence targetingNox4 knockdown cor-
responds to 59-GCTGTATATTGATGGTCCTTT-39 (TRCN0000046089).
Cells transduced with the MISSION nontarget shRNA control vector par-
ticles (Sigma-Aldrich) were used as controls. The undifferentiated podo-
cytes were seeded at 13106 cells per dish in a 100-mmdish and infected by
the lentivirus particles in the presence of 8 mg/ml polybrene, followed by
selection in puromycin (1 mg/ml; Sigma-Aldrich) for 4 days. The knock-
down efficiency in the cells was verified by RT-PCR andwas approximately
70% for Nox4. Nontarget and Nox4-shRNA–infected cells were then
cultured in RPMI with 5 mmol/L glucose or 25 mmol/L glucose or in
the presence or absence of TGF-b1 (5 ng/ml) and incubated for 48 hours
at 37°C. At the end of each experiment, cells were harvested and RNAwas
extracted by the TRIzolmethod and cDNAwas synthesized for quantitative
RT-PCR.
In Vitro Gene Expression Analyses
Gene expression was analyzed by real-time RT-PCR, using the
TaqMan system based on real-time detection of accumulated fluo-
rescence (ABI Prism 7500; PerkinElmer). Fluorescence for each cycle
was quantitatively analyzed by anABI Prism 7500 SequenceDetection
System (PerkinElmer). To control for variation in the amount ofDNA
that was available for PCR in the different samples, gene expression of
the target sequence was normalized in relation to the expression of an
endogenous control 18S ribosomal RNA (18S rRNATaqMan Control
Reagent Kit, ABI Prism 7500; PerkinElmer). Triplicate experiments
were performed, with six replicates each. Results were expressed
relative to control (untreated) cells, which was arbitrarily assigned a
value of 1. Human probe and primer sequences used for quantitative
RT-PCR are shown in Supplemental Table 2.
Measurement of ROS In Vitro
Fully differentiated normal, nontarget, and Nox4-shRNA infected
human podocytes were trypsinized and resuspended in 200 ml RPMI
media at a density of 104 cells per well of a white 96-well microplate
(PerkinElmer) and incubated at 37°C for 24 hours. Normal human
podocytes were then cultured with or without GKT137831 (10 mM)
for 2 hours and then treated with or without TGF-b1 (5 ng/ml) for 4
hours at 37°C. However, nontarget and Nox4-shRNA–infected cells
were cultured in normal glucose (5 mM) or in high glucose (25 mM)
for 2 days or in the presence or absence of TGF-b1 (5 ng/ml) for 4
hours at 37°C. Each well was washed with Krebs-HEPES, and 100 ml
of Krebs-HEPES supplemented with L-012 (100mM) (Wako Chemicals)
was subsequently added and incubated at 37°C for 10 minutes. After
incubation, plates were read on a luminometer (Berthold Technologies).
Statistical Analyses
All parameters were analyzed by one-way ANOVA using GraphPad
Prism 5 software (GraphPad Software, Inc., La Jolla, CA) for multiple
comparisons of the means or analyzed by the two-tailed unpaired
Mann–Whitney U test when required. A P value,0.05 was consid-
ered statistically significant. Results are expressed as the mean6SEM,
unless otherwise specified.
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SUPPLEMENTARY FIGURES LEGENDS AND TABLES  
 
Supplemental Figure1. Analysis of tubulointerstitial area by point counting method in the 






































Supplemental Figure 2. Analysis of Nox1, Nox2 and Nox4 mRNA levels in the renal cortex of 
control and diabetic ApoE
-/-
 mice (A) and Nox4 mRNA expression in tubular fraction of renal 
cortex (C). Analysis of protein expression of Nox4 in renal cortex and tubules after 20 weeks of 









immunofluorescence (B and D).   Data are the mean ± SEM. 
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Supplemental Figure 3. (a) Podocytes grown under permissive conditions (at 33 C display 
more characteristic cobblestone morphology. The cells form an epithelial monolayer as they 
reach confluence. (b) Differentiating (2 day) and (c and d) differentiated podocytes grown under 
nonpermissive conditions (10-14 days at 37 C). Under nonpermissive conditions, the cells 
develop interdigitating processes, which are only connected at sites of process interdigitations. 






















Supplemental Figure 4. Immunofluorescence staining for nephrin, synaptopodin and WT-1, 
with a blue nuclear counterstain (DAPI). Under nonpermissive conditions (at 37 C), the 
podocytes undergo growth arrest, display the typical arborized pattern of foot process extensions, 






















Supplemental Figure 5. Analysis of protein expression of Nox4 in podocytes cultured in NG 


















Supplemental Figure 6. shRNA to Nox4 downregulates Nox4 but not the Nox1, Nox2 or Nox5 
mRNA levels in human podocytes. Analysis of Nox isoform mRNA levels in cultured 
differentiated human podocytes in normal glucose RPMI medium. Data are the mean ± SEM. 
#


























Genes  Probe Sequence  Forward Primer 5’-3’  Reverse Primer 5’-3’  
5’FAM-3”TAMRA  
Nox1 CTAGAATAGCTACTGCCCACC GACCAATGTGGGACAATGAGTTT CCCCCACCGCAGACTTG 
Nox2 CAACTGGACAGGAACCT AGTGCGTGTTGCTCGACAAG CCAAGCTACCATCTTATGGAAAGT 
Nox4 CATTTTGCTATTTCATCAAA AAAAATATCACACACTGAATTCGAGACT TGGGTCCACAGCAGAAAACTC 
MCP1 AATGGGTCCAGACATAC GTCTGTGCTGACCCCAAGAAG TGGTTCCGATCCAGGTTTTTA 
NFκB-p65 AGCTCAAGATCTGCCG TCTCACATCCGATTTTTGATAACC CGAGGCAGCTCCCAGAGTT 
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Supplemental Table 2. Human probe and primer sequences for qRT-PCR 
Genes Probe Sequence Forward Primer 5’-3’ Reverse Primer 5’-3’ 
5’FAM-3”TAMRA 
Nox1 AAAGCAATTGGATCACAAC TTGCAGCCGCACACTGA GGCCACCAGCTTGTGGAA 
Nox2 CCTCCTGCCATGACT AGAGGGTTGGAGGTGGAGAATT GCACAAGGAGCAGGACTAGATGA 
Nox4 TCCATTTGCATCAATACT GGCTGGAGGCATTGGAGTAA CCAGTCATCCAACAGGGTGTT 
P47phox TGAGCCATACGTCGCC CCCTGAGCCCAACTATGCA CCACAGCAGTGTAGGCCTTGA 
Collagen IV ATTTGCGTAACTAACACACC CAATATGAAAACCGTAAAGTGCCTTATA CAGCAAGTAGAGGTCAATGAAGCA 
Fibronectin TGCCATTTGCTCCTGC AGAACAGTGGCAGAAGGAATATCTC CCCGCTGGCCTCCAA 
CTGF ACTGCCTGGTCCAGAC GCGGCTTACCGACTGGAA GGAACAGGCGCTCCACTCT 
α-SMA TGCCAGATCTTTTCC ACCCTGAAGTACCCGATAGAACAT CAACACGAAGCTCATTGTAGAAAGA 
VEGF CCCACTGAGGAGTCC CGAGGGCCTGGAGTGTGT CGCATAATCTGCATGGTGATG 
MCP1 CAGGAAACCAATATCCA CAAAGCAGGGCTCGAGTTG CCTGGGACTAGACTTGATGTCTCA 
NFκB-p65 AGCTCAAGATCTGCCG CTCATCCCATCTTTGACAATCGT TGCACCTTGTCACACAGTAGGAA 
 
 FAM, 5’-Fluorescein; α-SMA, smooth muscle actin; CTGF, connective tissue transforming growth factor; VEGF, vascular endothelial growth factor ; MCP1, 







Immunofluorescence   
Human podocytes were grown on coverslips, washed twice with PBS.  Renal frozen sections 
(4µm) and podocytes were fixed in 4% paraformaldehyde for 15 minutes, permeabilized using 
0.1% tritonX and incubated in a blocking buffer (1% BSA, 0.25% TritonX in PBS, pH 7.4). 
Primary and secondary antibodies were diluted in blocking buffer, and the tissue sections and 
cells with primary antibodies were incubated overnight at 4°C.  Coverslips were then mounted 
onto glass microscope slides and tissue sections were coversliped using Prolog Gold antifade 
reagent with DAPI (Invitrogen, Carlsbad, CA) or TO-PRO-3 (Invitrogen). Primary antibodies 
used included the following: Nox4 (rabbit polyclonal anti-Nox4, Abcam, Cambridge, MA, 
USA), nephrin (Santa Cruz Biotechnology, Santa Cruz, CA), synaptopodin (Santa Cruz 
Biotechnology, Santa Cruz, CA) and WT-1 (Santa Cruz Biotechnology, Santa Cruz, CA). 
Secondary antibodies used for immunofluorescence detection included Alexa Fluor 488 (rabbit 
anti-goat, Invitrogen, Eugene, Oregon, USA), Alexa Fluor 546 (goat anti-rabbit, Invitrogen, 
Eugene, Oregon, USA). All stained sections and cells were examined using an Olympus (Tokyo, 
Japan) BX61 fluorescence microscope, and images were captured on a Zeiss 510 Meta laser 
scanning confocal microscope (Zeiss, Germany) using LSM 510 software (version 3.2 SP2; 
Zeiss) or an Olympus BX61 fluorescence microscope. 
 
Tubulointerstitial (TI) Area 
Three micrometer kidney sections were stained with periodic acid–Schiff (PAS) for assessment 
of tubulointerstitial (TI) area in the renal cortex by using a point-counting technique routinely 
used method 
1
.  Briefly, in each field, 100 points were counted on a 1 cm
2
 eyepiece graticule 
with 10 equidistant grid lines. A total of 12 high-power fields (x400) per section were counted 
for each animal in all groups in the corticomedullary field. Each high-power field was 
0.076mm
2
, and the total area counted on the power slide was 0.91mm
2
. Tubulointerstitial area = 







RT-PCR in tubular fraction of renal cortex 
Tubules were isolated from the renal cortex by sieving method. Briefly, medulla was separated 
from the frozen kidney. Tubular fraction was obtained by mincing with the renal cortex with 
scalpel, and grinding the homogenate through a 100-mm disposable filter using a rubber syringe 
plunger. The saline-washed flow through material was passed through a 70-mm disposable filter, 
collected, and stored as the tubular fraction which was used for the RNA extraction for gene 




1.  Hewitson TD, Darby IA, Bisucci T et al. Evolution of tubulointerstitial fibrosis in 
experimental renal infection and scarring. J Am Soc Nephrol 1998; 9: 632–642. 
 
